NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its earnings results on Thursday, November, 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.01. The firm had revenue of $1.45 million for the quarter, compared to analysts' expectations of $3.56 million. View Kala Pharmaceuticals' Earnings History.

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Kala Pharmaceuticals.

4 analysts have issued twelve-month price objectives for Kala Pharmaceuticals' stock. Their forecasts range from $9.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $21.25 in the next year. This suggests a possible upside of 419.6% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

News articles about KALA stock have been trending somewhat negative recently, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Kala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,940,000 shares, an increase of 6.8% from the October 31st total of 3,690,000 shares. Based on an average daily trading volume, of 292,500 shares, the short-interest ratio is presently 13.5 days. Currently, 15.2% of the company's stock are short sold. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Aprea Therapeutics (APRE), Viking Therapeutics (VKTX), Provention Bio (PRVB), Clovis Oncology (CLVS), Lexicon Pharmaceuticals (LXRX), RAPT Therapeutics (RAPT), Prothena (PRTA), Morphic (MORF), Magenta Therapeutics (MGTA), Stemline Therapeutics (STML), Crinetics Pharmaceuticals (CRNX), Organogenesis (ORGO), Catalyst Pharmaceuticals (CPRX), Emisphere Technologies (EMIS) and Dynavax Technologies (DVAX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Paratek Pharmaceuticals (PRTK), REDHILL BIOPHAR/S (RDHL), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Dynavax Technologies (DVAX).

(KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.62%), State Street Corp (0.93%), Point72 Asset Management L.P. (0.90%), Boston Partners (0.36%), Wedbush Securities Inc. (0.26%) and Barclays PLC (0.04%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Kala Pharmaceuticals.

KALA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., State Street Corp, Wedbush Securities Inc. and Boston Partners. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $4.09.

Kala Pharmaceuticals has a market capitalization of $141.28 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]